Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLSNASDAQ:CNTXNASDAQ:ORMPOTCMKTS:PVOTF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$1.47+5.0%$1.48$1.10▼$2.43$81.70M2.93143,257 shs77,868 shsCNTXContext Therapeutics$0.57+1.6%$0.74$0.49▼$2.75$51.36M1.87281,281 shs151,137 shsORMPOramed Pharmaceuticals$2.13-0.9%$2.22$1.82▼$3.09$87.01M1.63148,112 shs96,723 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis0.00%+10.53%0.00%+12.21%-22.22%CNTXContext Therapeutics0.00%-9.02%-17.36%-25.05%-73.49%ORMPOramed Pharmaceuticals0.00%0.00%+0.47%-8.97%-7.39%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis2.798 of 5 stars3.55.00.00.00.02.50.6CNTXContext Therapeutics2.2846 of 5 stars3.62.00.00.00.61.71.3ORMPOramed Pharmaceuticals0.4003 of 5 stars0.04.00.00.00.00.80.6PVOTFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 3.00Buy$4.00172.11% UpsideCNTXContext Therapeutics 3.20Buy$6.00947.85% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/APVOTFBetterLife Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PVOTF, ORMP, CLLS, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/8/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/29/2025CNTXContext TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/29/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/21/2025CNTXContext TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/9/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$49.22M1.66N/AN/A$2.36 per share0.62CNTXContext TherapeuticsN/AN/AN/AN/A$1.27 per shareN/AORMPOramed Pharmaceuticals$2M43.51N/AN/A$3.61 per share0.59PVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)CNTXContext Therapeutics-$26.73M-$0.31N/AN/AN/AN/A-29.78%-29.08%8/6/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)PVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/ALatest PVOTF, ORMP, CLLS, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 million5/14/2025Q1 2025CNTXContext Therapeutics-$0.05-$0.05N/A-$0.05N/AN/A5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million3/27/2025Q4 2024ORMPOramed Pharmaceuticals-$0.03$0.01+$0.04$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.441.671.67CNTXContext TherapeuticsN/A48.8148.81ORMPOramed PharmaceuticalsN/A23.9423.94PVOTFBetterLife PharmaN/A3.623.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%CNTXContext Therapeutics14.03%ORMPOramed Pharmaceuticals12.73%PVOTFBetterLife PharmaN/AInsider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%CNTXContext Therapeutics3.04%ORMPOramed Pharmaceuticals13.70%PVOTFBetterLife Pharma34.77%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis29055.58 million46.46 millionOptionableCNTXContext Therapeutics789.70 million86.98 millionNot OptionableORMPOramed Pharmaceuticals1040.85 million35.25 millionOptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionablePVOTF, ORMP, CLLS, and CNTX HeadlinesRecent News About These CompaniesBetterLife Pharma Inc.May 19, 2025 | barrons.comBetterLife appoints Steven Sangha to board of directorsApril 1, 2025 | markets.businessinsider.comBetterLife Pharma Achieves Key Cardiac Safety MilestoneNovember 25, 2024 | markets.businessinsider.comBetterLife Pharma Inc BETRNovember 2, 2024 | morningstar.comOptimistic Buy Rating for BridgeBio Pharma’s BBP-812: Promising Phase 1/2 Results in Canavan Disease TherapyOctober 26, 2024 | markets.businessinsider.comBridgeBio Pharma’s BBP-812 Trial Shows Promise for Canavan Disease Amidst Focus on AcoramidisOctober 25, 2024 | markets.businessinsider.comBetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001October 23, 2024 | tmcnet.comWith election nearing, BMO analysts don't expect major pharma shake-ups from either candidateOctober 14, 2024 | fiercepharma.comAbortion, immigration, drug prices: Where Missouri’s candidates for U.S. Senate stand on the issuesOctober 13, 2024 | msn.comDemocrats snatch a major political football away from Republicans: freedomAugust 29, 2024 | yahoo.comRAMM Pharma Corp. (RAMM.CN)August 22, 2024 | uk.finance.yahoo.com‘Their skin was peeling off from the chemical burns’: Andhra reactor blast that killed 14 leaves trail of broken homesAugust 21, 2024 | indianexpress.comRewarding careers for animal loversAugust 13, 2024 | deccanherald.comState, city leaders announce deal for quantum technology facility on Chicago’s South SideJuly 27, 2024 | courthousenews.com$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management DrugsApril 26, 2024 | msn.comJardiance and Ofev propel Boehringer’s human pharma salesApril 17, 2024 | msn.comVertex Pharma scientist talks about the long road to developing non-addictive painkillersApril 15, 2024 | abcnews.go.comPharmacy defends Eli Lilly off-label drug suitApril 11, 2024 | lifesciencesipreview.comBetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 11, 2024 | tmcnet.comVictory Over Big Pharma Will Take More Than the IRAApril 4, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePVOTF, ORMP, CLLS, and CNTX Company DescriptionsCellectis NASDAQ:CLLS$1.47 +0.07 (+5.00%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.44 -0.02 (-1.70%) As of 06/20/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Context Therapeutics NASDAQ:CNTX$0.57 +0.01 (+1.58%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.60 +0.03 (+5.66%) As of 06/20/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Oramed Pharmaceuticals NASDAQ:ORMP$2.13 -0.02 (-0.93%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.13 0.00 (0.00%) As of 06/20/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.BetterLife Pharma OTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
